Comparative analysis between RQ ‐ PCR and digital droplet PCR of BCL 2/ IGH gene rearrangement in the peripheral blood and bone marrow of early stage follicular lymphoma
BCL 2/ IGH rearrangements were analysed by polymerase chain reaction ( PCR ) at diagnosis in paired peripheral blood ( PB ) and bone marrow ( BM ) samples from 67 patients with stage I/ II follicular lymphoma ( FL ). Real time quantitative PCR ( RQ ‐ PCR ) and digital droplet PCR (dd PCR ) were perf...
Gespeichert in:
Veröffentlicht in: | British journal of haematology 2017-05, Vol.177 (4), p.588-596 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | BCL
2/
IGH
rearrangements were analysed by polymerase chain reaction (
PCR
) at diagnosis in paired peripheral blood (
PB
) and bone marrow (
BM
) samples from 67 patients with stage I/
II
follicular lymphoma (
FL
). Real time quantitative
PCR
(
RQ
‐
PCR
) and digital droplet
PCR
(dd
PCR
) were performed in cases with a major breakpoint region (MBR+) at diagnosis and after localized radiotherapy and rituximab administration in order to investigate the applicability of dd
PCR
. The overall dd
PCR
/
RQ
‐
PCR
concordance was 81·9% (113/138 samples) and 97·5% in the 40/138 with quantifiable disease (
RQ
‐
PCR
≥10
−5
). At baseline, dd
PCR
allowed the recovery of a MBR+ marker in 8/18 (44·4%) samples that resulted MBR‐negative/minor cluster region‐negative/minor
BCL2
‐negative by qualitative
PCR
. Moreover, the tumour burden at diagnosis significantly predicted progression‐free survival (
PSF
) only when quantified by dd
PCR
. Paired
PB
and
BM
samples analysis demonstrated a high concordance in the detection of
BCL
2/IGH+
cells by qualitative and quantitative methods; in particular, 40/62 samples were positive by dd
PCR
(25 PB+/BM+; 9 PB+/BM−; 6 PB−/BM+), with 34/40 (85%) identified by the study of
PB
only. In conclusion, in localized
FL
, dd
PCR
is a promising tool for monitoring minimal residual disease (MRD) that is at least comparable to
RQ
‐
PCR
and potentially more accurate.
PB
is a suitable source for serial
BCL
2/
IGH
MRD
assessments, regardless of the methodology utilized. |
---|---|
ISSN: | 0007-1048 1365-2141 |
DOI: | 10.1111/bjh.14616 |